The global settlement costs a net $380.7 million, against $396.1 million in the bank at the end of September, and Liquidia drops the PH-ILD indication for its inhaled drug. Early indications put the stock up about 45%, a rebound that still leaves it near half its value before the Sept. 30 patent ruling.
Liquidia bought certainty on Tuesday evening. The price was most of its balance sheet and one of its two markets.
All six cases between the two drugmakers will be dropped under a global settlement, Liquidia said. Its inhaled treprostinil, YUTREPIA, will stay on the market for pulmonary arterial hypertension, or PAH, "without disruption." In exchange, Liquidia will not appeal a Sept. 30 ruling that two claims of a United Therapeutics patent covering use in pulmonary hypertension associated with interstitial lung disease, known as PH-ILD, are valid and infringed. The company has stopped marketing YUTREPIA for that use and has filed with the Food and Drug Administration to take it off the label.
The payments
The total comes to a net $380.7 million in three pieces. Liquidia will pay United Therapeutics $175 million within 30 business days, a figure that already nets out money United Therapeutics is paying Liquidia to settle a separate antitrust case. It will pay $60.3 million this month to other parties with interests in that antitrust case. The remaining $145.4 million comes in two $72.7 million payments, one by the end of January 2027 and one by the end of April.
That is about 96% of the $396.1 million of cash and equivalents Liquidia reported, on a preliminary and unaudited basis, at Sept. 30. About $235 million is due within roughly six weeks.
Liquidia's chief financial officer said the company expects to fund the payments "from the ongoing sales of YUTREPIA and cash on hand," citing preliminary third-quarter net product sales of $222.7 million. "We expect to rebuild our cash position and fund our planned clinical studies without requiring additional financing," he said. The settlement total equals about 1.7 quarters of current sales.
What was given up
The agreement covers PAH. According to Liquidia's own risk disclosures, it "does not extend to indications other than PAH or to new treprostinil-containing products," and United Therapeutics "may assert patents against our development programs or future products." That leaves the company's pipeline, including L606, which it is studying for PAH and PH-ILD, outside the protection of the deal. Liquidia also listed "the impact of ceasing PH-ILD promotion and sales on YUTREPIA revenue" as a risk but did not say how much of current sales came from that indication.
The price
Liquidia closed Tuesday at $26.81, down 3.11%, before the 5:44 p.m. announcement. In after-hours trading the stock reached as high as $42.05, and early Wednesday indications sat near $38.86, about 45% above the close. That still leaves it about 45% below the $70.69 close on Sept. 29, the day before the ruling.
Multiply the drop by roughly 89 million shares and the market value still missing since the ruling comes to about $2.8 billion, more than seven times what the settlement costs. One way to read that difference is as the market's estimate of what PH-ILD and the pipeline exposure were worth, though it rests on thin early trading. United Therapeutics, which closed at $543.40, is up about 13% since Sept. 29.
Market implications
One reading is that Liquidia removed its largest tail risk. Before the settlement the remedy after the ruling was open, and broader restrictions on YUTREPIA were possible. Now the PAH franchise is secure, all litigation ends, and the cost is spread into April 2027.
A second reading is that the company paid heavily for a smaller business. Nearly all of its cash goes out the door, the PH-ILD market is gone, and the pipeline remains exposed to new claims. The stock's position far below its pre-ruling level suggests investors see a permanently smaller franchise.
What to watch
Wednesday's open is the first test of the after-hours jump. November's earnings call is the first chance for Liquidia to say how much of YUTREPIA's revenue came from PH-ILD and how much cash is left after the October payments. The FDA must also act on the label request.